for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Innovent Biologics Says Study Of TYVYT Met Primary Endpoint Of Overall Survival

May 14 (Reuters) - Innovent Biologics Inc:

* PHASE 2 ORIENT-2 STUDY INVESTIGATING TYVYT MET PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up